Genome

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Retrieved on: 
Thursday, March 28, 2024
Research, Technology, Semiconductor, Genetics, Nanotechnology, Biotechnology, Hardware, Health, Data Management, Science, Genetic variation, Panel, NHGRI, Twist Bioscience, Twist, WES, Genome, Doctor of Philosophy, Sequence, Production, Exome, Silicon

In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “When companies such as Twist utilize our reference standard to create research tools, it facilitates scientists’ study of genetic variation.
  • The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
  • If interested in the Human Pangenome Spike-in Panel for the Twist Exome 2.0 panel, please complete the contact form here: https://www.twistbioscience.com/contact

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
Thursday, March 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Retrieved on: 
Wednesday, March 20, 2024
COVID-19, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, TVGN, COVID, Mutation, Immunotherapy, Patient, DNP, SARS-CoV-2, Genome, Peptide

Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.

Key Points: 
  • Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.
  • TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides.
  • TVGN 489’s peptide targets have been preserved in all previously studied COVID strains.
  • Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, including the currently dominant JN.1 strain and newer JN.1 strains, show that 96% of these CTLs remain active against the current circulating variants.

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Other Science, Technology, Research, General Health, Engineering, Manufacturing, Pharmaceutical, Other Professional Services, Medical Devices, Health Technology, Finance, Genetics, Nanotechnology, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Health, Hardware, Science, Innovation Center station, Gene editing, Cell, BRIC, RNA, Pear VC, Conscience, Capital, Messenger, Hope, Genome, Doctor of Philosophy, Bayer, Antibody, Kendall Square, CRISPR, Drug development, Multimedia, Small RNA, Silicon, Fine chemical

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Key Points: 
  • Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
  • Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications.
  • The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
  • “We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC.

World-Renowned Ancient DNA Expert, HHMI Investigator, and MacArthur Award Winner Beth Shapiro, Ph.D., Joins Colossal as Chief Science Officer

Retrieved on: 
Tuesday, March 19, 2024
Environment, Research, Genetics, Environmental Issues, Environmental Health, Biotechnology, Health, Other Science, Science, Genomics, Gene, Executive Committee, National Geographic Explorer, Woolly mammoth, Cell, University, Pennsylvania State University, Television, Life, DNA, Stanford University, CRISPR, Ice, Vertebrate Genomes Project, Hologenomics, Genome, HHMI, Colossal Biosciences, Balliol College, Oxford, Howard Hughes Medical Institute, Ecology and Evolutionary Biology, CSO, Domestication, Natural history, National academy, American Academy, Biology, Searle, George Church, Multimedia, MacArthur Fellows Program, Hunting

Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.

Key Points: 
  • Colossal Biosciences, the world’s first de-extinction company, today announced that Beth Shapiro, Ph.D. , internationally renowned evolutionary molecular biologist, leader in paleogenomics, and ancient DNA expert, has joined as Chief Science Officer.
  • In this role, she will oversee the continued expansion of the company’s de-extinction and conservation science teams.
  • A MacArthur “Genius Grant” Award winner and National Geographic Explorer, Beth Shapiro is a pioneer in the scientific fields of ancient DNA and paleogenomics.
  • “She’s the author of inspiring books 'How to Clone a Mammoth' and 'Life as We Made It,' plus an HHMI and MacArthur Fellow.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
Wednesday, March 13, 2024
Health Technology, Other Health, Technology, Oncology, General Health, Medical Devices, Neurology, Other Technology, Cardiology, Science, Biotechnology, Software, Other Science, Health, Research, PTA, Genome, Gene expression, Transcriptome, DNA, RNA, Figure skating jumps, Marketing, Workflow, Data, Genomics, SVS, WGA, Antibiotics

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists

Retrieved on: 
Tuesday, March 12, 2024
Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Database, Genetic testing, Disease, Intelligence, Risk, Library, Patient, RNA, DNA, Cancer, Medicine, Genome, Biology, Clinical trial, Neoplasm, Genomics, Liquid biopsy, HRD, Therapy, Collection, Physician

Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

Key Points: 
  • Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus , a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.
  • As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext® and CancerNext-Expanded® assays.
  • “Tempus has a powerful offering for tissue and liquid biopsy DNA and RNA profiling and somatic testing.
  • Now, with our germline testing and variant assessment expertise behind Tempus xG and xG+, we are poised to create a future where paired somatic and germline testing is the standard.

Cannabis Genetics Company Phylos Announces Elite Seeds: High-Potency, Production-Ready F1 Hybrid Seeds for Controlled Environments

Retrieved on: 
Tuesday, April 2, 2024
F1, Genetics, Candy, Genome, Seed, Plant, Inbreeding, Cannabis, Research and development, Cheese, Marker beacon, Economics, Agriculture

PORTLAND, Ore., April 2, 2024 /PRNewswire/ -- Cannabis genetics company Phylos® has added 10 Elite varieties to its growing menu of proprietary F1 hybrid seeds. Phylos Elites produce uniform plants that outperform clones and improve the economics of commercial indoor and controlled-environment operations.

Key Points: 
  • Elite cannabis seeds produce uniform genetics that outperform clones with higher yields, lower production costs, stress tolerance, and HLVd-resistance
    PORTLAND, Ore., April 2, 2024 /PRNewswire/ -- Cannabis genetics company Phylos® has added 10 Elite varieties to its growing menu of proprietary F1 hybrid seeds.
  • "Elite seeds generate vigorous plants that produce premium, standardized consumer products while reducing notoriously high costs of operating indoor and greenhouse grows," noted Ralph Risch, Phylos CEO.
  • "To our knowledge, Elites are the first seeds bred and validated to perform in high-stress, rapid cycle time, controlled environments."
  • Phylos F1 hybrid Elite seeds can be easily trialed in the same room as clones for cultivators to quickly see how seeds are the future of large-scale, cost-efficient cannabis production.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Retrieved on: 
Monday, April 1, 2024
HER2, IHC, CNTN4, Mutation, Genome, NSCLC, Immunotherapy, Breast, Patient, Neoplasm, ERBB2, Biomarker, Cancer, AI, Pembrolizumab, Medicine, AACR, Simple squamous epithelium, Therapy, Stomach, PD-L1, Annual general meeting

SEOUL, South Korea, April 1, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, California, from April 5 to 10.

Key Points: 
  • In a poster presentation, Lunit's AI-powered HER2 analyzer, Lunit SCOPE HER2's precision shines through its analysis of 194,259 pan-cancer samples, correlating different ERBB2 mutations with changes in HER2 protein expression.
  • Through detailed HER2 intensity examination, the AI analysis highlighted that, among ERBB2-mutated cases with HER2 IHC images, a higher proportion of HER2 3+ tumor cells was observed in S310x and ex20ins cases compared to others.
  • Similarly, high HER2 expression was observed in both S301x and ex20ins cases compared to other mutation cases.
  • Visit Lunit at booth 808 to explore how the Lunit SCOPE suite is revolutionizing oncology research and clinical practice.